 |
 |

The Cutting Edge
SHAN R. BAKER, MD
Arch Otolaryngol Head Neck Surg. 1988;114(6):621.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
 |
 |
Preclinical data suggest that platinum coordination complexes play an important role in the modulation of radiation damage. Clinical data thus far indicate encouraging preliminary results with simultaneous cisplatin and radiotherapy for patients with extensive locoregional disease. Carboplatin, a second-generation platinum analogue, has shown comparable antitumor activity in head and neck cancer, but less toxicity than the parent compound. In order to determine the safety and efficacy of simultaneous treatment with carboplatin and irradiation, 18 patients with advanced unresectable stage IV disease have entered an ongoing phase I and II study with weekly treatments of carboplatin at 60 mg/m2 (two patients), 75 mg/m2 (seven patients), and 100 mg/m2 (nine patients) given simultaneously, and for the duration of conventional radiotherapy. Preliminary results of this study were reported by Eisenberger and coworkers at the recent Second International Head and Neck Oncology Research Conference. Treatment was given on an outpatient basis
. . . [Full Text PDF of this Article]
Author Affiliations
Ann Arbor, Mich
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
|